{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:11:38Z","timestamp":1773911498327,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.clinthera.2010.06.004","type":"journal-article","created":{"date-parts":[[2010,7,16]],"date-time":"2010-07-16T08:53:18Z","timestamp":1279270398000},"page":"1188-1204","source":"Crossref","is-referenced-by-count":55,"title":["Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects"],"prefix":"10.1016","volume":"32","author":[{"given":"Akiko","family":"Sarashina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Sesoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyoshi","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Horie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva U.","family":"Graefe-Mody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Juergen","family":"Woerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus A.","family":"Dugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.06.004_bib1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.06.004_bib2","first-page":"S62","article-title":"Diagnosis and classification of diabetes mellitus","volume":"32","year":"2009","journal-title":"Diabetes Care."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.06.004_bib4","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/dmrr.296","article-title":"Diabetes trends in Japan","volume":"18","author":"Kawamori","year":"2002","journal-title":"Diabetes Metab Res Rev."},{"key":"10.1016\/j.clinthera.2010.06.004_bib5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11892-005-0013-4","article-title":"Diabetes in Japan","volume":"5","author":"Hirose","year":"2005","journal-title":"Curr Diab Rep."},{"key":"10.1016\/j.clinthera.2010.06.004_bib6","first-page":"741","article-title":"Frequency of the atypical aldehyde dehydrogenase-2 gene (ALDH2(2)) in Japanese and Caucasians","volume":"43","author":"Shibuya","year":"1988","journal-title":"Am J Hum Genet."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2010.06.004_bib7","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0168-8227(00)00174-1","article-title":"Genetic and environmental interaction in Japanese type 2 diabetics","volume":"50","author":"Matsuoka","year":"2000","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.clinthera.2010.06.004_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jama.291.3.335","article-title":"Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes","volume":"291","author":"Saydah","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.06.004_bib9","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.2337\/dc08-0469","article-title":"Baseline quality-of-care data from a quality-improvement program implemented by a network of diabetes outpatient clinics","volume":"31","author":"Rossi","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2010.06.004_bib10","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/diacare.24.10.1815","article-title":"The Diabetes Quality Improvement Project: Moving science into health policy to gain an edge on the diabetes epidemic [published correction appears in Diabetes Care. 2002;25:249]","volume":"24","author":"Fleming","year":"2001","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.06.004_bib11","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.amjmed.2009.12.008","article-title":"Current issues in the treatment of type 2 diabetes. Overview of newer agents: Where treatment is going","volume":"123","author":"DeFronzo","year":"2010","journal-title":"Am J Med."},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2010.06.004_bib12","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.3949\/ccjm.76.s5.02","article-title":"Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus","volume":"76","author":"Blonde","year":"2009","journal-title":"Cleve Clin J Med."},{"key":"10.1016\/j.clinthera.2010.06.004_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1745-6215-10-82","article-title":"Design, statistical analysis and sample size calculation of a phase IIb\/III study of linagliptin versus voglibose and placebo","volume":"10","author":"Horie","year":"2009","journal-title":"Trials."},{"key":"10.1016\/j.clinthera.2010.06.004_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF03346373","article-title":"Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents","volume":"31","author":"Pitocco","year":"2008","journal-title":"J Endocrinol Invest."},{"issue":"2","key":"10.1016\/j.clinthera.2010.06.004_bib15","first-page":"CD006739","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus","author":"Richter","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.clinthera.2010.06.004_bib16","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diabetes.53.9.2181","article-title":"Therapeutic strategies based on glucagon-like peptide 1","volume":"53","author":"Deacon","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2010.06.004_bib17","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes","volume":"27","author":"Ahr\u00e9n","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2010.06.004_bib18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1185\/030079906X162746","article-title":"Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes","volume":"23","author":"Pratley","year":"2007","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2010.06.004_bib19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.287.3.360","article-title":"Oral antihyperglycemic therapy for type 2 diabetes: Scientific review","volume":"287","author":"Inzucchi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.06.004_bib20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","article-title":"Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes","volume":"55","author":"Mu","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2010.06.004_bib21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2337\/diabetes.51.4.943","article-title":"Long-term treatment with the dipeptidyl peptidase IV inhibitor P32\/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa\/fa) Zucker rats","volume":"51","author":"Pospisilik","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2010.06.004_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejphar.2008.04.018","article-title":"Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob\/ob mice","volume":"588","author":"Moritoh","year":"2008","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.clinthera.2010.06.004_bib23","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2337\/diacare.28.8.1936","article-title":"Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year","volume":"28","author":"Ahr\u00e9n","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2010.06.004_bib24","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1210\/jc.2004-2460","article-title":"Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves modelassessed beta-cell function in patients with type 2 diabetes","volume":"90","author":"Mari","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2010.06.004_bib25","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2010.06.004_bib26","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effect of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2010.06.004_bib27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1620\/tjem.216.249","article-title":"Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet","volume":"216","author":"Koh","year":"2008","journal-title":"Tohoku J Exp Med."},{"key":"10.1016\/j.clinthera.2010.06.004_bib28","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/jm701280z","article-title":"8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes","volume":"50","author":"Eckhardt","year":"2007","journal-title":"J Med Chem."},{"key":"10.1016\/j.clinthera.2010.06.004_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/jpet.107.135723","article-title":"(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors","volume":"325","author":"Thomas","year":"2008","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2010.06.004_bib30","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270008323753","article-title":"Safety, tolerability, pharmaco-kinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers","volume":"48","author":"H\u00fcttner","year":"2008","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.06.004_bib31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1463-1326.2009.01046.x","article-title":"Pharmacokinetics, pharmaco-dynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients","volume":"11","author":"Heise","year":"2009","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.clinthera.2010.06.004_bib32","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1185\/03007990903094361","article-title":"Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects","volume":"25","author":"Graefe-Mody","year":"2009","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2010.06.004_bib33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/dmd.109.031476","article-title":"The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans","volume":"38","author":"Blech","year":"2010","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.clinthera.2010.06.004_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1517\/13543780903463862","article-title":"Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes","volume":"19","author":"Deacon","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2010.06.004_bib35","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1086\/302950","article-title":"Genomewide search for type 2 diabetes susceptibility genes in four American populations [published correction appears in Am J Hum Genet. 2002;70:284]","volume":"66","author":"Ehm","year":"2000","journal-title":"Am J Hum Genet."},{"key":"10.1016\/j.clinthera.2010.06.004_bib36","first-page":"3","article-title":"The lean patient with type 2 diabetes: Characteristics and therapy challenge [published correction appears in Int J Clin Pract Suppl. 2007;61:1776]","volume":"61","author":"Brunetti","year":"2007","journal-title":"Int J Clin Pract Suppl."},{"key":"10.1016\/j.clinthera.2010.06.004_bib37","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.metabol.2004.02.012","article-title":"Insulin secretion and insulin sensitivity at different stages of glucose tolerance: A cross-sectional study of Japanese type 2 diabetes","volume":"53","author":"Fukushima","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2010.06.004_bib38","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2337\/diacare.27.2.354","article-title":"Ethnic differences in insulin sensi tivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: The Study of Women's Health Across the Nation (SWAN)","volume":"27","author":"Torr\u00e9ns","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2010.06.004_bib39","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/sj.ijo.0801043","article-title":"Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese","volume":"23","author":"Ko","year":"1999","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.clinthera.2010.06.004_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1440-6047.1999.00091.x","article-title":"Manifestation of cardiovascular risk factors at low levels of body mass index and waist-to-hip ratio in Singaporean Chinese","volume":"8","author":"Deurenberg-Yap","year":"1999","journal-title":"Asia Pacific J Clin Nutr."},{"key":"10.1016\/j.clinthera.2010.06.004_bib42","series-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland","year":"1995"},{"key":"10.1016\/j.clinthera.2010.06.004_bib43","series-title":"Statistical Issues in Drug Development","author":"Senn","year":"1997"},{"key":"10.1016\/j.clinthera.2010.06.004_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/pst.147","article-title":"Nonlinear mixed effects modelling for estimation of steady state attainment","volume":"4","author":"Hoffman","year":"2005","journal-title":"Pharm Stat."},{"key":"10.1016\/j.clinthera.2010.06.004_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1211\/jpp.61.01.0008","article-title":"Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans","volume":"61","author":"Fuchs","year":"2009","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.clinthera.2010.06.004_bib46","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2147\/VHRM.S1707","article-title":"Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes","volume":"4","author":"Richter","year":"2008","journal-title":"Vasc Health Risk Manag."},{"key":"10.1016\/j.clinthera.2010.06.004_bib47","series-title":"Presented at: 66th Scientific Sessions of the American Diabetes Association","article-title":"Multiple dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy Japanese subjects","author":"Narita","year":"2006"},{"key":"10.1016\/j.clinthera.2010.06.004_bib48","series-title":"Presented at: 68th Scientific Sessions of the American Diabetes Association","article-title":"Pharmacokinetics, pharmaco-dynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects","author":"Hirayama","year":"2008"},{"key":"10.1016\/j.clinthera.2010.06.004_bib49","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","article-title":"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses","volume":"78","author":"Herman","year":"2005","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.06.004_bib50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/bdd.662","article-title":"Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats","volume":"30","author":"Fuchs","year":"2009","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.clinthera.2010.06.004_bib51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2169\/internalmedicine.48.1691","article-title":"A cross-sectional survey of chronic kidney disease and diabetic kidney disease in Japanese type 2 diabetic patients at four urban diabetes clinics","volume":"48","author":"Watanabe","year":"2009","journal-title":"Intern Med."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810001955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810001955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T14:23:24Z","timestamp":1544365404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810001955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0149291810001955"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.06.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}